Evertz Pharma Becomes First German Firm to Add Bitcoin to Balance Sheet

Evertz Pharma, a pharmaceutical company, has made a significant move by becoming the first public company in Germany to add Bitcoin to its balance sheet. This decision reflects a growing trend among corporations worldwide that are increasingly recognizing the value of digital assets in diversifying their portfolios and safeguarding against economic uncertainties.

Germany, known for its cautious regulatory environment, has seen increasing interest in digital assets. However, no public company had taken this step—until now. Evertz Pharma’s Bitcoin investment signals a strong belief in crypto’s future as a reliable store of value. By holding Bitcoin, the company isn’t just hedging against inflation or currency devaluation; it’s also positioning itself as a forward-thinking business ready to embrace financial innovation.

Evertz Pharma’s decision mirrors a global trend started by companies like MicroStrategy and Tesla. These firms gained international attention for shifting parts of their treasury into Bitcoin, citing long-term value and financial independence. Germany’s crypto laws are among the most advanced in Europe, allowing regulated investment and custody. This regulatory clarity likely influenced Evertz Pharma’s confidence in making such a move. It could also open the door for other German firms to follow suit.

Evertz Pharma GmbH, a company specializing in premium natural cosmetics, has made history by becoming the first German firm to adopt a strategic Bitcoin reserve model. The company's journey with Bitcoin commenced on December 21, 2020, when it made its initial investment by purchasing Bitcoin worth €2 million. This move marked the beginning of Evertz Pharma's commitment to integrating digital assets into its financial strategy.

In May 2025, Evertz Pharma further solidified its position in the cryptocurrency market by acquiring an additional 100 BTC, valued at approximately €10 million. This purchase not only expanded the company's digital asset reserve but also underscored its long-term vision for financial stability. Managing Director Dominik Evertz highlighted that Bitcoin, being a scarce and globally tradable asset, complements the company's reserves and aligns with its forward-thinking strategy.

The decision to add Bitcoin to its balance sheet is a significant step for Evertz Pharma, as it demonstrates the company's confidence in the potential of digital currencies to enhance financial resilience. By embracing Bitcoin, Evertz Pharma is positioning itself at the forefront of a growing trend among corporations that are increasingly recognizing the value of digital assets in diversifying their portfolios and safeguarding against economic uncertainties.

This strategic move by Evertz Pharma is likely to influence other German companies to consider similar investments in Bitcoin, as the benefits of holding digital assets become more apparent. The company's proactive approach to integrating Bitcoin into its financial strategy serves as a model for other firms looking to adapt to the evolving landscape of global finance.